 |
인쇄하기
취소
|
New insights into Brilinta
The efficacy of AstraZeneca’s Brilinta (ticagrelor), a platelet aggregation inhibitor, has been re-evaluated in advanced countries including the United States, United Kingdom and Germany.
In a study of 44 American patients with acute coronary syndromes (ACS) who did not respond to clopidogrel, the antiplatelet effect of ticagrelor was superior to prasugrel, and the results were featured in t...
In a study of 44 American patients with acute coronary syndromes (ACS) who did not respond to clopidogrel, the antiplatelet effect of ticagrelor was superior to prasugrel, and the results were featured in t...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.